• Contact info@abtriva.com for inquiries and orders.
  • Chinese (Simplified)

  • English

  • German

  • Korean

  • Spanish

United States (English / $ USD)

Recombinant Human Calreticulin-3 (CALR3)

ACP12596

Number
Order Exclusive Products Now

Request a Quote
High Purity LevelsPrecision and ReliabilityCustomization Options

Specifications


Cat.No ACP12596 Target NameCALR3
Target SynonymsCALR 3; CALR3; CALR3_HUMAN; Calreticulin 2; Calreticulin-2; Calreticulin-3; Calreticulin2; Calreticulin3; Calsperin; Cancer/testis antigen 93; CMH19; CRT2; CT93; FLJ25355; MGC26577FormLyophilized powder
Expression SystemCustom Production. Please inquire and provide the desire expression system.Expression Range20-384
Protein LengthFull Length of Mature ProteinPurity>85% (SDS-PAGE)
Storage Buffer5%-50% glycerol. Lyophilized powder form: the buffer before lyophilization is Tris/PBS-based buffer, 6% Trehalose, Liquid form: default storage buffer is Tris/PBS-based buffer, pH 8.0.

Immunogen Information


Target SpeciesHumanUniprot IDQ96L12
Background Information
  • Uniprot Id

    Q96L12

  • Target Species

    Human

  • Target Name

    CALR3

  • Target Full Name

    Calreticulin-3

  • Target Function

    During spermatogenesis, may act as a lectin-independent chaperone for specific client proteins such as ADAM3. Required for sperm fertility. CALR3 capacity for calcium-binding may be absent or much lower than that of CALR.

  • Target Involvement

    Cardiomyopathy, familial hypertrophic 19 (CMH19)

  • Target Subcellular Location

    Endoplasmic reticulum lumen.

  • Target Protein Families

    Calreticulin family

  • Target Tissue Specificity

    Testis specific.

  • Target Synonyms

    CALR 3; CALR3; CALR3_HUMAN; Calreticulin 2; Calreticulin-2; Calreticulin-3; Calreticulin2; Calreticulin3; Calsperin; Cancer/testis antigen 93; CMH19; CRT2; CT93; FLJ25355; MGC26577

Inquire Recombinant Human Calreticulin-3 (CALR3) Now



AbTriva respects your privacy and protects your personal data in accordance with AbTriva. For more information, please see our data protection statement. *

Notification